Home > Insider Trading > Filing (0001209191-21-011484)

Filing Details

Accession Number:: 0001209191-21-011484
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-17 18:44:21
Reporting Period:: 2021-02-11

Accepted Time:: 2021-02-17 18:44:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1364719	Michael Kauffman	C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-11	6,601	$15.52	562,821	No	4	S	Direct
Common Stock	Acquisiton	2021-02-15	21,800	$0.00	584,621	No	4	M	Direct
Common Stock	Disposition	2021-02-11	6,642	$15.52	764,147	No	4	S	Indirect	By Spouse
Common Stock	Acquisiton	2021-02-15	21,800	$0.00	785,947	No	4	M	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	M	Direct
No	4	S	Indirect	By Spouse
No	4	M	Indirect	By Spouse

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2021-02-15	21,800	$0.00	21,800	$0.00
Common Stock	Restricted Stock Units	Disposition	2021-02-15	21,800	$0.00	21,800	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
43,600			No	4	M	Direct
43,600			No	4	M	Indirect

Footnotes

This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.
On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.